Markets:

Overview

News

Currencies

International

Treasuries

MiMedx Group, Inc - Common Stock (NQ:MDXG)

4.375 +0.245 (+5.93%)

Streaming Delayed Price Updated: 12:58 PM EDT, Aug 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about MiMedx Group, Inc - Common Stock

Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself

June 18, 2026

From Biotech Insider

Via GlobeNewswire

The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It

June 16, 2026

From World Street Intelligence

Via GlobeNewswire

A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus

June 09, 2026

Issued on behalf of Conexeu Sciences Inc.

From Equity Insider

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

May 19, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

May 12, 2026

From Pomerantz LLP

Via GlobeNewswire

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

April 30, 2026

From TELA Bio, Inc.

Via GlobeNewswire

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

July 17, 2024

From Cassava Sciences, Inc.

Via GlobeNewswire

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG

January 22, 2024

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

MDXG LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MDXG

January 17, 2024

From Rosen Law Firm

Via Business Wire

MIMEDX ALERT: Bragar Eagel & Squire, P.C. is Investigating MiMedx Group, Inc. on Behalf of MiMedx Stockholders and Encourages Investors to Contact the Firm

January 15, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

January 12, 2024

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

January 12, 2024

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

January 11, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study

August 15, 2023

MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers

From MediWound Ltd.

Via GlobeNewswire

MiMedx Group (NASDAQ: MDXG) Reports Q1 2023 Financial Results Showing 21.7% Sales Growth

May 03, 2023

MiMedx Group, Inc. (NASDAQ: MDXG) is engaged as a biotechnology company that is focused as a placental biologics developer to

Via Spotlight Growth

Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

November 15, 2022

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

Via FinancialNewsMedia

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.